These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 35251693)

  • 41. Liraglutide: A Glucagon-Like Peptide-1 Agonist for Chronic Weight Management.
    Manigault KR; Thurston MM
    Consult Pharm; 2016 Dec; 31(12):685-697. PubMed ID: 28074747
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting.
    Kaur P; Mahendru S; Mithal A
    Indian J Endocrinol Metab; 2016; 20(5):595-599. PubMed ID: 27730066
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Diabetes epidemiology in Russia: what has changed over the decade?].
    Shestakova MV; Vikulova OK; Zheleznyakova AV; Isakov MA; Dedov II
    Ter Arkh; 2019 Oct; 91(10):4-13. PubMed ID: 32598625
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Leptin: Less Is More.
    Zhao S; Kusminski CM; Elmquist JK; Scherer PE
    Diabetes; 2020 May; 69(5):823-829. PubMed ID: 32312898
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Short-term monotherapy with Liraglutide for weight management: A case study.
    Almarshad F
    J Family Med Prim Care; 2019 May; 8(5):1804-1806. PubMed ID: 31198765
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Predictors of Effectiveness of Glucagon-Like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes and Obesity.
    Babenko AY; Savitskaya DA; Kononova YA; Trofimova AY; Simanenkova AV; Vasilyeva EY; Shlyakhto EV
    J Diabetes Res; 2019; 2019():1365162. PubMed ID: 30944827
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study.
    Lapolla A; Berra C; Boemi M; Bossi AC; Candido R; Di Cianni G; Frontoni S; Genovese S; Ponzani P; Provenzano V; Russo GT; Sciangula L; Simioni N; Bette C; Nicolucci A;
    Adv Ther; 2018 Feb; 35(2):243-253. PubMed ID: 29270781
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature Review.
    Ostawal A; Mocevic E; Kragh N; Xu W
    Diabetes Ther; 2016 Sep; 7(3):411-38. PubMed ID: 27350545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Diabetes Remission Clinical Trial (DiRECT): protocol for a cluster randomised trial.
    Leslie WS; Ford I; Sattar N; Hollingsworth KG; Adamson A; Sniehotta FF; McCombie L; Brosnahan N; Ross H; Mathers JC; Peters C; Thom G; Barnes A; Kean S; McIlvenna Y; Rodrigues A; Rehackova L; Zhyzhneuskaya S; Taylor R; Lean ME
    BMC Fam Pract; 2016 Feb; 17():20. PubMed ID: 26879684
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Predictors of weight-loss response with glucagon-like peptide-1 receptor agonist treatment among adolescents with severe obesity.
    Nathan BM; Rudser KD; Abuzzahab MJ; Fox CK; Coombes BJ; Bomberg EM; Kelly AS
    Clin Obes; 2016 Feb; 6(1):73-8. PubMed ID: 26683756
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation.
    van Bloemendaal L; Veltman DJ; ten Kulve JS; Drent ML; Barkhof F; Diamant M; IJzerman RG
    Obesity (Silver Spring); 2015 Oct; 23(10):2075-82. PubMed ID: 26331843
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Markers of β-Cell Failure Predict Poor Glycemic Response to GLP-1 Receptor Agonist Therapy in Type 2 Diabetes.
    Jones AG; McDonald TJ; Shields BM; Hill AV; Hyde CJ; Knight BA; Hattersley AT;
    Diabetes Care; 2016 Feb; 39(2):250-7. PubMed ID: 26242184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of obesity on disability, function, and physical activity: data from the Osteoarthritis Initiative.
    Batsis JA; Zbehlik AJ; Barre LK; Bynum JP; Pidgeon D; Bartels SJ
    Scand J Rheumatol; 2015; 44(6):495-502. PubMed ID: 26083472
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictors of response to liraglutide in Japanese type 2 diabetes.
    Toyoda M; Yokoyama H; Abe K; Nakamura S; Suzuki D
    Diabetes Res Clin Pract; 2014 Dec; 106(3):451-7. PubMed ID: 25458335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastric bypass surgery attenuates ethanol consumption in ethanol-preferring rats.
    Davis JF; Schurdak JD; Magrisso IJ; Mul JD; Grayson BE; Pfluger PT; Tschöp MH; Seeley RJ; Benoit SC
    Biol Psychiatry; 2012 Sep; 72(5):354-60. PubMed ID: 22444202
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
    Esposito K; Mosca C; Brancario C; Chiodini P; Ceriello A; Giugliano D
    Curr Med Res Opin; 2011 Aug; 27(8):1519-28. PubMed ID: 21663496
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated circulating levels of an incretin hormone, glucagon-like peptide-1, are associated with metabolic components in high-risk patients with cardiovascular disease.
    Yamaoka-Tojo M; Tojo T; Takahira N; Matsunaga A; Aoyama N; Masuda T; Izumi T
    Cardiovasc Diabetol; 2010 May; 9():17. PubMed ID: 20470376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes.
    Mosikian AA; Golikova TI; Martjanova MV; Babenko AY
    Future Sci OA; 2022 Mar; 8(3):FSO779. PubMed ID: 35251693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.